AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 91 min read

StoneX maintains Buy rating on Enovix, $10 price target

StoneX kept a Buy rating on Enovix with a $10 price target, implying a 300% upside from the Oct 8 close of $2.50. The firm forecasts $85M in Q4 2028 revenue, with a 11.3x 2028 revenue multiple, citing growth potential and silicon-anode technology adoption.

Original reporting
tradingview.com
Published Oct 9, 2026, 1:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
StoneX maintains Buy rating on Enovix, $10 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could trigger short covering and attract new long positions.

02

Market read

Analyst upgrade for a micro‑cap may create short‑term price movement.

03

What to watch

Potential supply chain constraints for silicon‑anode technology.

Relevance 6/10Novelty 6/10Timing: today

Background

StoneX is a brokerage firm providing research coverage on emerging tech companies.

Market effects

Sector

May boost sentiment for battery and EV‑related stocks.

Regional

Limited to US markets where ENOV trades.

Global

Low, as Enovix is a micro‑cap.

Counterpoint

What could challenge this read

The target may be overly optimistic given execution risk.

Key entities

  • Research Firm
    StoneX

    Issuer of the analyst note.

  • Company
    Enovix

    Battery manufacturer receiving the new rating.

Read at source← All news

Related articles

OCT 6
$CRWDMed

CRWD Maintained by StoneX -- Price Target Raised to $325

StoneX analyst Yi Fu Lee maintained a 'Buy' rating on CrowdStrike (CRWD) and raised the price target from $250 to $325. The stock is currently priced at $272.67, which is 97.7% overvalued according to GF Value™. CrowdStrike's GF Score™ is 71/100, indicating strong growth and momentum but poor valuation. Insider activity shows significant selling, with $451 million in sales over the past three months.

gurufocus.com2 min
OCT 6
$TXRHMed

Texas Roadhouse upgraded to Buy from Hold at StoneX

StoneX upgraded Texas Roadhouse to Buy from Hold, setting a $200 price target. The analyst cites the company's leadership in casual dining and compelling risk/reward after a share pullback. Texas Roadhouse is seen as a high-quality operator that can widen its competitive advantage during economic stress.

tipranks.com1 min
OCT 2
$ROCMed

Rank One Computing stock price target maintained at $9 by StoneX

StoneX reiterated a Buy rating and $9 price target for Rank One Computing (NASDAQ:ROC), citing recent contract wins and improved pipeline velocity. The stock has fallen 44.6% over six months, trading at $4.05. The company reported a 2% revenue increase in Q2 2026, with a gross profit margin of nearly 80%. Management extended lock-up agreements until February 2027.

investing.com2 min
SEP 17
$SNEXMed

StoneX (SNEX) Turns Mortgage Bond Complexity Into New Revenue

StoneX Group (SNEX) launched a synthetic credit structure with DeltaTerra for mortgage bonds, enabling institutional investors to gain exposure via credit default swaps. The company reported strong fiscal Q3 results, with revenue up 47% and net income more than doubling. Growth was driven by commercial and institutional segments, while retail segment revenue declined. Interest expenses and variable costs increased, and a new structured product aims to capitalize on a market event. Hedge funds ha

insidermonkey.com2 min